90101-16-9

Basic information

• Product Name: Droxicam
• Synonyms: DROXICAM;5-Methyl-3-(2-pyridinyl)-2H，5 H-1，3-oxaZino[5，6-c][1，2]benzothiazine-2，4(3H)-dione-6，6-dioxide;Dobenam;Droxar;E-3128;Ombolan;5-Methyl-3-(2-pyridyl)-2H,5H-1,3-oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide;5-Methyl-3-(pyridin-2-yl)-2H,5H-1,3-oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide
• CAS NO: 90101-16-9
• Molecular Formula: C16H11N3O5S
• Molecular Weight: 357.34
• Mol File: 90101-16-9.mol

Chemical Properties

• Melting Point: 259-261°
• Boiling Point: 554.7°Cat760mmHg
• Flash Point: 289.3°C
• Appearance: /
• Density: 1.68g/cm³
• Vapor Pressure: 2.4E-12mmHg at 25°C
• Refractive Index: 1.747
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 3.80±0.19(Predicted)
• CAS DataBase Reference: Droxicam(CAS DataBase Reference)
• NIST Chemistry Reference: Droxicam(90101-16-9)
• EPA Substance Registry System: Droxicam(90101-16-9)

Safety Data

• Hazardous Substances Data: 90101-16-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Droxicam is used as a non-steroidal anti-inflammatory drug (NSAID) for its anti-inflammatory, analgesic, and antipyretic properties. It is particularly effective in the treatment of spinal osteoarthritis, providing relief from pain, inflammation, and fever associated with the condition.
Used in Pain Management:
Droxicam is used as a pain management agent for its analgesic properties, helping to alleviate pain and discomfort in various conditions, including spinal osteoarthritis and other inflammatory disorders.
Used in Antipyretic Therapy:
Droxicam is used as an antipyretic agent to reduce fever and associated symptoms in patients with inflammatory conditions or infections.
Used in Inflammatory Conditions:
Droxicam is used as an anti-inflammatory agent to manage inflammation in various conditions, such as spinal osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, among others.
Used in Gastrointestinal Protection:
Due to its lower ulcerogenic effect compared to other NSAIDs, droxicam is used as a gastrointestinal protective agent, offering a safer alternative for patients with a history of gastrointestinal issues or at risk of developing them while on NSAID therapy.

Originator

Esteve (Spain)

World Health Organization (WHO)

Droxicam is authorized to be marketed in many European countries. Although droxicam is metabolized to piroxicam, it is considered that the risk of hepatic damage differs from that shown by other NSAIDs products, including piroxicam.

InChI:InChI=1/C16H11N3O5S/c1-18-13-14(10-6-2-3-7-11(10)25(18,22)23)24-16(21)19(15(13)20)12-8-4-5-9-17-12/h2-9H,1H3

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 36322-90-4 Piroxicam 

Relevant articles and documents

Benzothiazine derivatives and their applications as medicinal products or as synthesis intermediates for medicinal products

The invention relates to the compounds corresponding to the general formula I STR1 in which: R1 represents a lower alkyl radical (having one to four carbon atoms), a phenyl radical or a benzyl radical. These compounds are useful as medicinal products or as synthesis intermediates for medicinal products.

Process for the preparation of oxazinobenzothiazine 6,6-dioxide derivatives

The present invention relates to a process for the preparation of a 5-methyl-3-heteroaryl-2H,5H-1,3-oxazino[5,6-c] [1,2] benzothiazine-2,4-(3H)-dione 6,6-dioxide of the general formula I: STR1 in which R represents a heteroraryl radical, preferably substituted or unsubstituted pyrimidinyl or pyridyl, of the type consisting in reacting an amide of the general formula II: STR2 in which R1 represents a heteroarylamino radical, preferably substituted or unsubstituted pyrimidinylamino or pyridylamino, with a compound of the general formula III: STR3 in which R2 represents a C1 to C4 lower alkyl radical such as methyl or ethyl, an aryl radical such as phenyl, or an alkylaryl radical such as benzyl, wherein the reaction is carried out in an organic solvent selected from the group comprising pyridine, substituted pyridines such as 4-dimethylaminopyridine, 4-(pyrrolidin-1-yl)pyridine and 2,6-ditert.-butyl-4-methylpyridine, and mixtures thereof.

Derivatives of oxazinobenzothiazine-6,6-dioxide

This invention relates to new derivatives of oxazinobenzothiazine-6,6-dioxide, to a process for the production thereof and to the use thereof as medicaments. The new derivatives according to the present invention correspond to the general formula I: STR1 wherein: R represents a linear or branched lower C1 -C4 alkyl radical, in particular the methyl and ethyl radicals, X represents an oxygen atom or a sulphur atom, and Het represents a mono- or bicyclic unsaturated heterocycle containing a nitrogen heteroatom in the ortho position relative to the link between the said heterocycle and the nitrogen atom of the oxazine ring, the said heterocycle optionally containing one or two other additional heteroatoms selected from nitrogen, oxygen and sulphur, and also being able to be substituted by one or two methyl radicals.